A new treatment option has been approved for the symptomatic treatment of patients with stable angina pectoris.
Angina pectoris, in layman’s terms, is chest pain associated with coronary heart disease—it occurs when the heart isn’t getting enough oxygen, normally due to narrowing or blockage of an artery.
Fortunately for those who are not receptive to first-line antianginal therapies, such as beta-blockers and calcium antagonists, a new drug from Mississauga-based KYE Pharmaceuticals Inc. has been approved by Health Canada.
The drug, CORZYNA provides a dose of ranolazine through extended-release tablets—ranolazine has been available internationally for well over a decade.
The drug is projected to hit the Canadian market by the spring of 2021.
- Male suffering from gunshot wounds following shooting in Brampton
- All COVID-19 cases at Hamilton grocery stores for the week of Jan 10 to 16
- All COVID-19 cases at Halton grocery stores for the week of Jan 10 to 16
“KYE is extremely pleased to be able to bring this important new class of an anti-anginal medication to Canadian patients and healthcare professionals” Doug Reynolds, president of KYE, said in a news release.
“This is a highlight for KYE and for those Canadian patients suffering from recurrent angina episodes,” he continued.